Financial reports
10-K
2023 FY
Annual report
21 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
10-K
2022 FY
Annual report
22 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
11 May 22
10-K
2021 FY
Annual report
23 Mar 22
10-Q
2021 Q3
Quarterly report
2 Dec 21
Current reports
8-K
Important Regulatory Milestone Supports Next Phase of CTIM-76 Development
1 Apr 24
8-K
Amendments to Articles of Incorporation or Bylaws
21 Mar 24
8-K
March 2024 Corporate Presentation Advancing Medicines for Solid Tumors
6 Mar 24
8-K
Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76
31 Oct 23
8-K
August 2023 Corporate Presentation Advancing Medicines for Solid Tumors
7 Aug 23
8-K
Other Events
20 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
2 Jun 23
8-K
Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
22 Mar 23
8-K
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
6 Feb 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
27 Jan 23
Registration and prospectus
S-8
Registration of securities for employees
21 Mar 24
S-8
Registration of securities for employees
22 Mar 23
424B3
Prospectus supplement
14 Nov 22
POS AM
Prospectus update (post-effective amendment)
9 Nov 22
S-3
Shelf registration
9 Nov 22
424B3
Prospectus supplement
9 Nov 22
424B3
Prospectus supplement
27 Sep 22
424B3
Prospectus supplement
11 Aug 22
424B3
Prospectus supplement
2 Aug 22
424B3
Prospectus supplement
3 Jun 22
Other
EFFECT
Notice of effectiveness
17 Nov 22
EFFECT
Notice of effectiveness
14 Nov 22
CORRESP
Correspondence with SEC
14 Nov 22
UPLOAD
Letter from SEC
14 Nov 22
EFFECT
Notice of effectiveness
8 Apr 22
EFFECT
Notice of effectiveness
17 Dec 21
CORRESP
Correspondence with SEC
14 Dec 21
UPLOAD
Letter from SEC
13 Dec 21
EFFECT
Notice of effectiveness
20 Oct 21
SEC STAFF
SEC staff action: Order
20 Oct 21
Ownership
4
Jennifer Lynn Minai-Azary
22 Mar 24
4
Alex C. Levit
22 Mar 24
4
Martin A. Lehr
22 Mar 24
SC 13G/A
Affinity Asset Advisors, LLC
13 Feb 24
SC 13G/A
Lehr Martin A.
7 Feb 24
SC 13G
Opaleye Management Inc.
5 Jan 24
4
Philip W. Kantoff
31 May 23
4
Linda West
31 May 23
4
Jennifer Evans Stacey
31 May 23
4
RICHARD J BERMAN
31 May 23